Literature DB >> 22878547

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission : results of a multivariate analysis.

C Matuschek1, E Bölke, S L Roth, K Orth, I Lang, H Bojar, J W Janni, W Audretsch, C Nestle-Kraemling, G Lammering, V Speer, S Gripp, P A Gerber, B A Buhren, R Sauer, M Peiper, M Schauer, M Dommach, K Struse-Soll, W Budach.   

Abstract

BACKGROUND: An earlier published series of neoadjuvant radiochemotherapy (NRT-CHX) in locally advanced noninflammatory breast cancer (LABC) has now been updated with a follow-up of more than 15 years. Long-term outcome data and predictive factors for pathologic complete response (pCR) were analyzed. PATIENTS AND METHODS: During 1991-1998, 315 LABC patients (cT1-cT4/cN0-N1) were treated with NRT-CHX. Preoperative radiotherapy (RT) consisted of external beam radiation therapy (EBRT) of 50 Gy (5 × 2 Gy/week) to the breast and the supra-/infraclavicular lymph nodes combined with an electron boost in 214 cases afterwards or-in case of breast conservation-a 10-Gy interstitial boost with (192)Ir afterloading before EBRT. Chemotherapy was administered prior to RT in 192 patients, and concomitantly in 113; 10 patients received no chemotherapy. The update of all follow-up ended in November 2011. Age, tumor grade, nodal status, hormone receptor status, simultaneous vs. sequential CHX, and the time interval between end of RT and surgery were examined in multivariate terms with pCR and overall survival as end point.
RESULTS: The total pCR rate after neoadjuvant RT-CHX reached 29.2%, with LABC breast conservation becoming possible in 50.8% of cases. In initially node-positive cases (cN+), a complete nodal response (pN0) after NRT-CHX was observed in 56% (89/159). The multivariate analysis revealed that a longer time interval to surgery increased the probability for a pCR (HR 1.17 [95% CI 1.05-1.31], p < 0.01). However, in large tumors (T3-T4) a significantly reduced pCR rate (HR 0.89 [95% CI 0.80-0.99], p = 0.03) was obtained. Importantly, pCR was the strongest prognostic factor for long-term survival (HR 0.28 [95% CI 0.19-0.56], p < 0.001).
CONCLUSION: pCR identifies patients with a significantly better prognosis for long-term survival. However, a long time interval to surgery (> 2 months) increases the probability of pCR after NRT-CHX.

Entities:  

Mesh:

Year:  2012        PMID: 22878547     DOI: 10.1007/s00066-012-0162-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  21 in total

1.  Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study.

Authors:  W K Hung; Y Lau; C M Chan; A W Yip
Journal:  Hong Kong Med J       Date:  2000-09       Impact factor: 2.227

2.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.

Authors:  Gunter von Minckwitz; Michael Untch; Eveline Nüesch; Sibylle Loibl; Manfred Kaufmann; Sherko Kümmel; Peter A Fasching; Wolfgang Eiermann; Jens-Uwe Blohmer; Serban Dan Costa; Keyur Mehta; Jörn Hilfrich; Christian Jackisch; Bernd Gerber; Andreas du Bois; Jens Huober; Claus Hanusch; Gottfried Konecny; Werner Fett; Elmar Stickeler; Nadia Harbeck; Volkmar Müller; Peter Jüni
Journal:  Breast Cancer Res Treat       Date:  2010-11-03       Impact factor: 4.872

3.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Authors:  B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

Review 4.  Dose fractionation and volume effects in normal tissues and tumors.

Authors:  H R Withers; H D Thames
Journal:  Am J Clin Oncol       Date:  1988-06       Impact factor: 2.339

Review 5.  Stem cells in mammary development and carcinogenesis: implications for prevention and treatment.

Authors:  Gabriela Dontu; Suling Liu; Max S Wicha
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

6.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

7.  Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.

Authors:  Stephan Ludwig Roth; Werner Audretsch; Hans Bojar; Innokentij Lang; Reinhart Willers; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2010-05-21       Impact factor: 3.621

8.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

9.  Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.

Authors:  Delphine Lerouge; Emmanuel Touboul; Jean-Pierre Lefranc; Catherine Genestie; Laurence Moureau-Zabotto; Jean Blondon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

10.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

Authors:  Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

View more
  13 in total

1.  Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall.

Authors:  M Linthorst; A N van Geel; E A Baartman; S B Oei; W Ghidey; G C van Rhoon; J van der Zee
Journal:  Strahlenther Onkol       Date:  2013-04-04       Impact factor: 3.621

2.  Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction : An alternative treatment option for locally advanced breast cancer.

Authors:  Montserrat Pazos; Stefanie Corradini; Darius Dian; Vera von Bodungen; Nina Ditsch; Rachel Wuerstlein; Stephan Schönecker; Nadia Harbeck; Heike Scheithauer; Claus Belka
Journal:  Strahlenther Onkol       Date:  2017-01-25       Impact factor: 3.621

3.  DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.

Authors:  Wilfried Budach; Christiane Matuschek; Edwin Bölke; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Frederick Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2015-05-12       Impact factor: 3.621

4.  Helical tomotherapy for inoperable breast cancer: a new promising tool.

Authors:  Ciprian Chira; Youlia M Kirova; Xavier Liem; François Campana; Dominique Peurien; Malika Amessis; Nathalie Fournier-Bidoz; Jean-Yves Pierga; Rémi Dendale; Pierre Bey; Alain Fourquet
Journal:  Biomed Res Int       Date:  2013-09-02       Impact factor: 3.411

Review 5.  Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.

Authors:  Elizabeth Miller; Hee Jin Lee; Amriti Lulla; Liz Hernandez; Prashanth Gokare; Bora Lim
Journal:  F1000Res       Date:  2014-08-19

6.  Helical TomoTherapy for locally advanced or recurrent breast cancer.

Authors:  M N Duma; C Heinrich; C Schönknecht; B Chizzali; M Mayinger; M Devecka; S Kampfer; S E Combs
Journal:  Radiat Oncol       Date:  2017-01-28       Impact factor: 3.481

7.  Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.

Authors:  Nobutaka Aoyama; Yasuhiro Ogawa; Miki Yasuoka; Hitomi Iwasa; Kana Miyatake; Rika Yoshimatsu; Tomoaki Yamanishi; Norihiko Hamada; Taiji Tamura; Kana Kobayashi; Yoriko Murata; Takuji Yamagami; Mitsuhiko Miyamura
Journal:  Oncol Lett       Date:  2016-12-01       Impact factor: 2.967

8.  Preoperative Radiotherapy Is Not Associated with Increased Post-mastectomy Short-term Morbidity: Analysis of 77,902 Patients.

Authors:  Pablo A Baltodano; Myrna Eliann Reinhardt; José M Flores; Francis M Abreu; Anmol Chattha; Lyonell Kone; Carisa M Cooney; Michele A Manahan; Richard C Zellars; Gedge D Rosson
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-03-13

9.  Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer.

Authors:  Nobutaka Aoyama; Yasuhiro Ogawa; Miki Yasuoka; Kenta Ohgi; Hitomi Iwasa; Kana Miyatake; Rika Yoshimatsu; Tomoaki Yamanishi; Norihiko Hamada; Taiji Tamura; Kana Kobayashi; Yoriko Murata; Mitsuhiko Miyamura; Takuji Yamagami
Journal:  Oncol Lett       Date:  2017-04-21       Impact factor: 2.967

Review 10.  Neoadjuvant Radio(chemo)therapy for Breast Cancer: An Old Concept Revisited.

Authors:  Christiane Matuschek; Carolin Nestle-Kraemling; Thorsten Kühn; Tanja Fehm; Edwin Bölke; Stefanie Corradini; Gerd Fastner; Kitti Maas; Clemens Seidel; Wilfried Budach
Journal:  Breast Care (Basel)       Date:  2020-04-14       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.